Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076492 · ClinicalTrials.gov registry record · Phase 2
NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485
A Phase 2 study of Parkinson Disease, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 1
- Study location
NCT00076492: Completed Phase 2 study of Parkinson Disease, sponsored by University of Rochester.
NCT00076492 is a Phase 2 study of Parkinson Disease that has completed, run by University of Rochester. The registered enrollment target is 195 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00076492, a Phase 2 study of Parkinson Disease, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to assess the impact of CoQ10 and GPI 1485 on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.
Conditions Studied
Interventions
- DRUG CoQ10
- DRUG GPI 1485
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00076492 record still lists
NCT00076492 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which CoQ10 is the first listed.
NCT00076492 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00076492 about?
NCT00076492 is a clinical study titled "NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485". The goal of this study is to assess the impact of CoQ10 and GPI 1485 on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.
What is the current status of trial NCT00076492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2004-01. Estimated completion is 2005-09.
What conditions does trial NCT00076492 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT00076492?
The interventions under investigation include: CoQ10 (DRUG), GPI 1485 (DRUG).
Who is sponsoring clinical trial NCT00076492?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076492 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00076492's enrollment target sits among peer trials
195 50th of 297 higher than 248 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia